Haematopoietic Growth Factors in Children With Neutropenia

Lehrnbecher, Thomas; Welte, Karl

doi:10.1046/j.1365-2141.2002.03230.x

Cited by 58 publications

(46 citation statements)

References 229 publications

(353 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The C level of consensus was generated by the opinion of some expert who considered this procedure too tight. If initial ANC is 0.5-1.0 Â 10 9 /L (moderate neutropenia) three further counts at least seven days apart are recommended [8][9][10] and if initial values are confirmed, first level investigations (Table VI) need to be carried out (EO, 8.3, D). The low level of consensus was due the fact that not all experts considered this level of neutropenia worthy of investigating that promptly.…”

Section: Diagnostic Itinerarymentioning

confidence: 99%

“…Performance of bone marrow aspiration and trephine biopsy in deep sedation was strongly encouraged. Indirect anti-neutrophil antibodies detection by flow cytometry was agreed on to be the most useful and practical method for identifying the autoimmune neutropenia (AIN) [1,7,9,17,[42][43][44][45][46]. The low sensitivity (74% at first assessment) [45] of this method was recognized by the panel but it was considered, in the respect of diagnostic power, less detrimental than the lower specificity (very high number of false positives) of the direct method [44] (III, V, EO, 9, A).…”

Section: (Eo 9 A)mentioning

confidence: 99%

“…In case of confirmed neutropenia with non-informative first level investigations and no signs/symptoms specific for associated forms, the panel agreed on the need to perform bone marrow aspiration for morphology [1,7,9,12,14,17,48] (EO, 9, A). The panel also agreed on the appropriateness of taking on this occasion marrow samples also for cytogenetic, immunophenotyping, cultures, and molecular analysis and to carry out these tests only in case morphological examination showed dysplastic or atypical cells or significantly reduced cellularity in the fragments of the marrow smear (EO, 8.8, B).…”

Section: (Eo 9 A)mentioning

confidence: 99%

“…At this stage of the pathway, if no maturation block on marrow morphology is detected, and the indirect antibodies test against neutrophils are negative at least four times, the diagnosis of idiopathic neutropenia (IN) is considered appropriate [1,[7][8][9]17,46] (EO, 9,A). Since IN still remains an exclusion diagnosis the panel agreed on the need to place IN patients on a monitoring program and to perform diagnostic re-evaluation in case new elements suggestive of other diagnosis arise (EO, 9, A).…”

Section: (Eo 9 A)mentioning

confidence: 99%

See 3 more Smart Citations

Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica)

Fioredda

Calvillo

Bonanomi

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Congenital and acquired neutropenia are rare disorders whose frequency in pediatric age may be underestimated due to remarkable differences in definition or misdiagnosed because of the lack of common practice guidelines. Neutropenia Committee of the Marrow Failure Syndrome Group (MFSG) of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica) elaborated this document following design and methodology formerly approved by the AIEOP board. The panel of experts reviewed the literature on the topic and participated in a conference producing a document which includes a classification of neutropenia and a comprehensive guideline on diagnosis of neutropenia. Pediatr Blood Cancer 2011;57:10–17. © 2011 Wiley‐Liss, Inc.

show abstract

Section: Diagnostic Itinerarymentioning

confidence: 99%

Section: (Eo 9 A)mentioning

confidence: 99%

Section: (Eo 9 A)mentioning

confidence: 99%

Section: (Eo 9 A)mentioning

confidence: 99%

See 2 more Smart Citations

Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica)

Fioredda

Calvillo

Bonanomi

et al. 2011

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Patients with severe neutropenia (Ͻ100 granulocytes/ mm 3 ) are at greatest risk (9,10), and the mortality rate for patients developing pneumonia in this setting can be as high as 67% (4). With the advent of stem cell transplantation and the use of colonystimulating factors, the duration of neutropenia post-BMT has been significantly shortened (11)(12)(13)(14)(15). Despite this, immunodeficiency can persist, and patients remain at increased risk for pulmonary infections.…”

Section: Defective Phagocytosis and Clearance Of Pseudomonas Aeruginomentioning

confidence: 99%

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Ojielo

Cooke²,

Mancuso

et al. 2003

The Journal of Immunology

128

View full text Add to dashboard Cite

Bone marrow transplantation (BMT) is an important therapeutic option for a variety of malignant and nonmalignant disorders. Unfortunately, BMT recipients are at increased risk of infection, and in particular, pulmonary complications occur frequently. Although the risk of infection is greatest during the neutropenic period immediately following transplant, patients are still vulnerable to pulmonary infections even after neutrophil engraftment. We evaluated the risk of infection in this postengraftment period by using a well-established mouse BMT model. Seven days after syngeneic BMT, B6D2F1 mice are no longer neutropenic, and by 3 wk, they demonstrate complete reconstitution of the peripheral blood. However, these mice remain more susceptible throughout 8 wk to infection after intratracheal administration of Pseudomonas aeruginosa; increased mortality in the P. aeruginosa-infected BMT mice correlates with increased bacterial burden in the lungs as well as increased systemic dissemination. This heightened susceptibility to infection was not secondary to a defect in inflammatory cell recruitment to the lung. The inability to clear P. aeruginosa in the lung correlated with reduced phagocytosis of the bacteria by alveolar macrophages (AMs), but not neutrophils, decreased production of TNF-α by AMs, and decreased levels of TNF-α and IFN-γ in the bronchoalveolar lavage fluid following infection. Expression of the β2 integrins CD11a and CD11c was reduced on AMs from BMT mice compared with wild-type mice. Thus, despite restoration of peripheral blood count, phagocytic defects in the AMs of BMT mice persist and may contribute to the increased risk of infection seen in the postengraftment period.

show abstract

Management of Infection in Children with Bone Marrow Failure

Chakravorty¹,

Hann²

2006

Pediatric Hematology

View full text Add to dashboard Cite

Haematopoietic Growth Factors in Children With Neutropenia

Cited by 58 publications

References 229 publications

Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica)

Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica)

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Management of Infection in Children with Bone Marrow Failure

Contact Info

Product

Resources

About